LM11A-31: Clinical Trials

3 trials of LM11A-31, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 enrolling by invitation, 1 not yet recruiting, 1 recruiting. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1
Phase 11Not yet recruiting 1

Follow LM11A-31: new trials by email Literature Review of LM11A-31 trials Research Report on LM11A-31

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment
LM11A-31, Placebo - HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)
Phase 1 / Phase 2Not yet recruitingUniversity of North Carolina, Chapel Hill682026-11-012026-11-18
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31
LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy
Phase 2Enrolling by invitationAdam Boxer1472026-07-292026-11-05
The Progressive Supranuclear Palsy Clinical Trial Platform
AADvac1, LM11A-31 - Progressive Supranuclear Palsy(PSP)
Phase 2RecruitingAdam Boxer4402026-07-292026-11-18

Conditions studied

Supranuclear Palsy, Progressive (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Cognitive Dysfunction (1)  ·  Frontotemporal Dementia (1)  ·  Memory Disorders (1)

Sponsors

Adam Boxer (2)  ·  University of North Carolina, Chapel Hill (1)

Countries

United States (3)

Top investigators

Adam Boxer, MD, PhD (2)  ·  Anne-Marie Wills, MD (2)  ·  Irene Litvan, MD (2)  ·  Julio Rojas-Martinez, MD, PhD (2)  ·  Monica Diaz, MD, MS (1)  ·  Rick Meeker, PhD (1)

NIH funding

R01AG085029 (2), R01AG082540 (1)